| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
|
J Virol
|
2004
|
2.11
|
|
2
|
The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome.
|
Nat Genet
|
2004
|
1.82
|
|
3
|
Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.
|
J Natl Cancer Inst
|
2004
|
1.80
|
|
4
|
Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.
|
Cancer Res
|
2002
|
1.53
|
|
5
|
Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.
|
J Virol
|
2005
|
1.50
|
|
6
|
A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.
|
J Virol
|
2010
|
1.50
|
|
7
|
X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D.
|
J Virol
|
2007
|
1.45
|
|
8
|
BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186.
|
J Virol
|
2005
|
1.30
|
|
9
|
Virally targeted therapies for EBV-associated malignancies.
|
Oncogene
|
2003
|
1.29
|
|
10
|
Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.
|
Cancer Res
|
2006
|
1.28
|
|
11
|
Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.
|
J Virol
|
2005
|
1.22
|
|
12
|
Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters.
|
PLoS Pathog
|
2009
|
1.20
|
|
13
|
B cell terminal differentiation factor XBP-1 induces reactivation of Kaposi's sarcoma-associated herpesvirus.
|
FEBS Lett
|
2007
|
1.16
|
|
14
|
ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells.
|
J Virol
|
2007
|
1.14
|
|
15
|
The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
|
J Virol
|
2010
|
1.12
|
|
16
|
An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.
|
J Virol
|
2012
|
1.10
|
|
17
|
The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1.
|
J Virol
|
2004
|
1.10
|
|
18
|
BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function.
|
Virology
|
2004
|
1.09
|
|
19
|
Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism.
|
Proc Natl Acad Sci U S A
|
2010
|
1.07
|
|
20
|
Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alpha-induced signaling and apoptosis by downregulating tumor necrosis factor receptor 1.
|
J Virol
|
2004
|
1.06
|
|
21
|
Epstein-Barr virus-specific methylation of human genes in gastric cancer cells.
|
Infect Agent Cancer
|
2010
|
1.04
|
|
22
|
The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli.
|
J Virol
|
2012
|
1.03
|
|
23
|
Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9.
|
J Biol Chem
|
2007
|
1.00
|
|
24
|
Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase.
|
J Virol
|
2010
|
0.99
|
|
25
|
MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair.
|
J Invest Dermatol
|
2012
|
0.96
|
|
26
|
Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication.
|
J Virol
|
2012
|
0.95
|
|
27
|
Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.
|
J Virol
|
2002
|
0.95
|
|
28
|
Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa.
|
Dig Dis Sci
|
2012
|
0.94
|
|
29
|
Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease.
|
Int J Cancer
|
2007
|
0.92
|
|
30
|
The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
|
PLoS Pathog
|
2012
|
0.89
|
|
31
|
Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency.
|
J Virol
|
2011
|
0.88
|
|
32
|
The Epstein-Barr virus protein BMRF1 activates gastrin transcription.
|
J Virol
|
2005
|
0.88
|
|
33
|
Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas.
|
Mol Cancer Ther
|
2005
|
0.87
|
|
34
|
CCAAT/enhancer binding proteins alpha and beta regulate the tumor necrosis factor receptor 1 gene promoter.
|
Mol Immunol
|
2009
|
0.87
|
|
35
|
Viral response to chemotherapy in endemic burkitt lymphoma.
|
Clin Cancer Res
|
2010
|
0.87
|
|
36
|
The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2- and p53-dependent manner.
|
J Virol
|
2011
|
0.86
|
|
37
|
Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells.
|
J Virol
|
2013
|
0.85
|
|
38
|
The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins.
|
J Virol
|
2010
|
0.84
|
|
39
|
Simian virus 40 T/t antigens and lamin A/C small interfering RNA rescue the phenotype of an Epstein-Barr virus protein kinase (BGLF4) mutant.
|
J Virol
|
2010
|
0.84
|
|
40
|
The Epstein-Barr virus polymerase accessory factor BMRF1 adopts a ring-shaped structure as visualized by electron microscopy.
|
J Biol Chem
|
2004
|
0.83
|
|
41
|
Epstein-Barr virus WZhet DNA can induce lytic replication in epithelial cells in vitro, although WZhet is not detectable in many human tissues in vivo.
|
Intervirology
|
2009
|
0.83
|
|
42
|
The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1.
|
J Virol
|
2013
|
0.83
|
|
43
|
LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
|
J Clin Invest
|
2014
|
0.82
|
|
44
|
Mice engrafted with human fetal thymic tissue and hematopoietic stem cells develop pathology resembling chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2013
|
0.81
|
|
45
|
Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.
|
J Virol
|
2014
|
0.78
|
|
46
|
Human NKT cells direct the differentiation of myeloid APCs that regulate T cell responses via expression of programmed cell death ligands.
|
J Autoimmun
|
2011
|
0.78
|
|
47
|
Hsp90 inhibitors: a potential treatment for latent EBV infection?
|
Cell Cycle
|
2010
|
0.76
|